Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PLX-R18 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| PLX-R18 | EXPERIMENTAL | Dose Escalation- first three subjects will be enrolled in the low dose cohort, 6 subjects in the intermediate-dose cohort, and 15 subjects in the high dose cohort. |
| Name | Type | Description |
|---|---|---|
| PLX-R18 | BIOLOGICAL | Intramuscular (IM) administration of PLX-R18 |
Inclusion Criteria: 1. Age ≥18 years. 2. At least 3 months after HCT, either autologous or allogeneic (of any source, with any preparatory regimen, for any indication), prior to study treatment. 3. Sustained platelet count ≤50,000/µL, and/or sustained Hb ≤8 g/dL and/or sustained ANC ≤1000/mm3, attr...
PLX-R18 is an investigational therapy being developed for incomplete hematopoietic cell transplantation (HCT), a condition where blood cell recovery is incomplete after a hematopoietic cell transplant. It is intended to address the unmet need in patients with incomplete hematopoietic recovery following transplantation.
PLX-R18 is being developed by Pluri Inc., a biopharmaceutical company. Pluri Inc. is publicly traded on the stock exchange under the ticker symbol PLUR.
PLX-R18 is currently in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still undergoing clinical trials to evaluate its safety and efficacy.
PLX-R18 has one completed Phase 1 clinical trial, identified by the National Clinical Trial number NCT03002519. This trial was a safety evaluation of intramuscular injections of PLX-R18 in subjects with incomplete hematopoietic recovery following hematopoietic cell transplantation. The trial enrolled 21 participants and was conducted in the United States and Israel.
Yes, PLX-R18 is classified as a monoclonal antibody. It is being investigated for its potential to treat incomplete hematopoietic cell transplantation by targeting specific mechanisms involved in blood cell recovery.